EVALUATING THE RESULTS OF RECONSTRUCTIVE SURGERY TREATMENT IN PATIENTS WITH XANTHELASMA PALPEBRARUM AT CAN THO UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL IN 2023-2024
Main Article Content
Abstract
Background: The most common form of cutaneous xanthoma is called xanthelasma palpebrarum. It is characterized by yellowish plaques on the eyelid skin. While it is a harmless condition that does not affect functionality, it significantly impacts the patient’s social and emotional well-being due to its cosmetic implications. There are different ways to treat the condition mentioned, but the most common and effective method is surgery. Objectives: To describe the clinical characteristics of patients with xanthelasma palpebrarum and evaluate the treatment outcomes of reconstructive surgery in patients with xanthelasma palpebrarum at the Can Tho University of Medicine and Pharmacy Hospital in 2023-2024. Materials and methods: A prospective crosssectional descriptive was conducted on 32 patients who underwent xanthelasma palpebrarum reconstructive surgery at the Can Tho University of Medicine and Pharmacy Hospital. Results: The average age of the study group was 51.16±8.41 years old, mainly concentrated between 46-70 years old (68.75%), female (93.75%). 26/48 lesions appeared on the upper eyelid (54.16%), 18/32 patients had a total size >10mm2 (56.25%), 21/32 patients were classified as Lee's grade I (65.62%). After surgery, 100% of patients had no infection or impact on the levator muscle. 6/32 patients had a trace of stitches in the wound (18.8%), 96.9% of patients had good wound healing, 96.9% of patients were satisfied with the treatment results, no complications were recorded during the 30-day follow-up period. Conclusions: The treatment outcomes met the patients’ needs, as evidenced by their high satisfaction levels. No complications were observed in the one-month post-surgery.
Keywords
Xanthelasma Palpebrarum, Reconstructive surgery
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Marilho T.D. Eyelid Xanthelasma: surgical treatment as the first choice. SciELO Brasil. 2022. 37(4), 498-504, doi:10.5935/2177-1235.2022.
3. Nair P.A., Singhal R. Xanthelasma palpebrarum – a briefreview. Clin Cosmet Investig Dermatol. 2017. 11, 1-5, doi:10.2147/CCID.S130116.
4. Rai A., Karki S., Sah S.P., Kamat L.N., Pradhan M. Dyslipidemia in Patients with Xanthelasma Palpebrarum Visiting the Department of Dermatology of a Tertiary Care Centre: A Descriptive sectional Study. JNMA J Nepal Med Assoc. 2022. 60(250), 529-532, doi: 10.31729/jnma.7485.
5. Kim Y.G., Oh J.W., Lee K.C., Yoon S.H. Clinical association between serum cholesterol level and the size of xanthelasma palpebrarum. Arch Craniofac Surg. 2022. 23(2), 71-76, doi: 10.7181/acfs.2022.00185.
6. Lee H.Y., Jin U.S., Minn K.W., Park Y.O. Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg. 2013. 40(4), 380-386, doi:10.5999/aps.2013.40.4.380.
7. Bộ Y tế. Hướng dẫn phòng ngừa nhiễm khuẩn vết mổ. 2012.461.
8. Trần Thiết Sơn. Các vấn đề cơ bản trong phẫu thuật tạo hình thẩm mỹ. Nhà xuất bản Y học Hà Nội. 2014. 72-76.
9. Kose R. Treatment of large xanthelasma palpebrarum with full-thickness skin grafts obtained by blepharoplasty. J Cutan Med Surg. 2013. 17(3), 197-200, doi: 10.2310/7750.2012.12065.
10. Yang Y., Sun J., Xiong L., Li Q. Treatment of xanthelasma palprbrarum by upper eyelid skin flap incorporating blepharoplasty. Aesthetic Plast Surg. 2013. 37(5), 882-886, doi:10.1007/s00266 -013-0195-0.